

DAFTAR PUSTAKA

1. Lesmana CR, Hasan I, Gani RA, Sanitioso A, Setiawan PB, Djumhana A, Konsensus nasional penatalaksanaan Hepatitis B di Indonesia 2017.editor :Lesmana CR.PPHI. Jakarta ;2017:1-82
2. World Health Organization. Hepatitis B [Internet]. WHO; [diakses pada 16 Jan 2024]. Tersedia pada: <https://www.who.int/news-room/fact-sheets/detail/Hepatitis-b>
3. Kemenkes RI. Laporan Hasil Riset Kesehatan Dasar (Riskesdas). Jakarta: Badan Penelitian dan Pengembangan Kesehatan. 2018.
4. Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. *Annals of translational medicine*. 2017 Feb;5(3).
5. Marugán RB, Garzón SG. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. *World journal of gastroenterology: WJG*. 2009 Jan 1;15(4):423.
6. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF- β as major players and therapeutic targets. *Journal of cellular and molecular medicine*. 2006 Jan;10(1):76-99.
7. Wu SD, Wang JY, Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. *World journal of gastroenterology: WJG*. 2010 Jan 1;16(4):501.
8. Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, et al. Global prevalence of chronic hepatitis B virus infection and related liver disease: a systematic review and meta-analysis. *Rev Med Virol*. 2018;28(6):e1985.
9. Liu J, Wang S, Zhang Y, Fan R, Chen Y, Zhu Y, et al. Global prevalence of significant liver fibrosis in chronic hepatitis B patients: a systematic review and meta-analysis. *J Viral Hepat*. 2023;30(1):86-97.
10. Lesmana CRA, Gani RA, Hasan I, Simadibrata M, Sulaiman AS, Pakasi LS, et al. Significant hepatic fibrosis among chronic hepatitis B patients in Jakarta, Indonesia. *J Gastroenterol Hepatol*. 2020;35(9):1564-1569.

11. Gani YI, Yusuf I, Patellongi IJ, Massi MN. Prevalence of advanced liver fibrosis and associated factors among chronic hepatitis B patients in Makassar, Indonesia. *F1000Res.* 2022;11:234.
12. Lee KG, Seo YS, An H, Um SH, Jung ES, Keum B, Yim HJ, Jeon YT, Chun HJ, Kim CD, Ryu HS. Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B. *Journal of gastroenterology and hepatology.* 2010 Jan;25(1):94-100.
13. Zeng DW, Dong J, Liu YR, Jiang JJ, Zhu YY. Noninvasive models for assessment of liver fibrosis in patients with chronic hepatitis B virus infection. *World Journal of Gastroenterology.* 2016 Aug 8;22(29):6663.
14. Huang R, Jiang N, Yang R, Geng X, Lin J, Xu G, Liu D, Chen J, Zhou G, Wang S, Luo T. Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B. *Experimental and therapeutic medicine.* 2016 May 1;11(5):1673-7.
15. Cross TJ, Rizzi P, Berry PA, Bruce M, Portmann B, Harrison PM. King's Score: an accurate marker of cirrhosis in chronic hepatitis C. *European journal of gastroenterology & hepatology.* 2009 Jul 1;21(7):730-8.
16. Marpaung YA, Sembiring J, Zain LH. Accuracy of liver fibrosis degree based on King's score to Fibroscan in chronic hepatitis B. *The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy.* 2016 Jun 2;17(1):10-5.
17. Wang L, Fan YX, Dou XG. Declining diagnostic accuracy of non-invasive fibrosis tests is associated with elevated alanine aminotransferase in chronic hepatitis B. *World Journal of Clinical Cases.* 2018 Oct 10;6(12):521.
18. Karacaer Z, Avci O, Yilmaz KF. KING's Score may be More Effective in the Determination of Severe Fibrosis in Chronic Hepatitis B Infections. *Viral hepatitis Journal/Viral Hepatit Dergisi.* 2017 Apr 1;23(1).
19. Lemoine M, Shimakawa Y, Nayagam S, Khalil M, Suso P, Lloyd J, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver Fibrosis and cirrhosis in patients with chronic VHB infection in West Africa. *Gut.* 2016 Aug 1;65(8):1369-76.

20. Wang RQ, Zhang QS, Zhao SX, Niu XM, Du JH, Du HJ et al. Gamma-glutamyl transpeptidase to platelet ratio index is a good noninvasive biomarker for predicting liver Fibrosis in Chinese chronic hepatitis B patients. *Journal of International Medical Research*. 2016 Dec;44(6):1302-13.
21. Ren T, Wang H, Wu R, Niu J. Gamma-Glutamyl Transpeptidase-to-Platelet Ratio Predicts Significant Liver Fibrosis of Chronic Hepatitis B Patients in patients with chronic hepatitis B. *World Journal of Gastroenterology*. 2017
22. Nov 11;23(41):7425.
23. Shire NJ. Cure strategies for hepatitis B virus: the promise of immunotherapy. *clinical pharmacology in drug development*. 2017 Mar;6(2):186-94.
24. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 a core group report. *Journal of Hepatology*. 2011 Nov 1;55(5):1121-31.
25. Lee JM, Ahn SH. Quantification of HBsAg: basic virology for clinical practice. *World journal of gastroenterology: WJG*. 2011 Jan 1;17(3):283.
26. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos (t) ide analogue treatment of chronic hepatitis B: new trick of old dog. *Journal of Gastroenterology*. 2013 Jan;48(1):13-21.
27. Dienstag JL. Hepatitis B virus infection. *New england journal of medicine*. 2008 Oct 2;359(14):1486-500.
28. Lavanchy D. Worldwide epidemiology of VHB infection, disease burden, and vaccine prevention. *Journal of clinical virology*. 2005 Dec 1;34:S1-3.
29. Feld J, Janssen HL, Abbas Z, Elewaut A, Ferenci P, Isakov V, et al. World gastroenterology organisation global guideline hepatitis B: September 2015. *Journal of Clinical Gastroenterology*. 2016 Oct 1;50(9):691-703.

30. Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*. 2018 Apr;67(4):1560-99.
31. Konerman MA, Lok AS. Epidemiology, diagnosis, and natural history of hepatitis B. In: Sanyal AJ, et al. *Zakim and Boyer's hepatology: A Textbook of Liver Disease 7th Edition*. Philadelphia: Elsevier. 2018. P474-84
32. Busch K, Thimme R. Natural history of chronic hepatitis B virus infection. *Medical microbiology and immunology*. 2015 Feb;204(1):5-10.
33. Sharma A, Nagalli S. Chronic liver disease. InStatPearls [Internet] 2022 Dec 25. StatPearls Publishing.
34. Grigorescu M. Noninvasive biochemical markers of liver fibrosis. *Journal of gastrointestinal and liver diseases: JGLD*. 2006 Jun 1;15(2):149-59.
35. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. *Clinica chimica acta*. 2006 Feb 1;364(1-2):33-60.
36. Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. *Experimental Biology and Medicine*. 2020 Jan;245(2):96-108.
37. Bataller R, Brenner DA. Liver fibrosis. *The journal of clinical investigation*. 2005 Feb 1;115(2):209-18.
38. Nallagangula KS, Nagaraj SK, Venkataswamy L, Chandrappa M. Liver fibrosis: A compilation on the biomarkers status and their significance during disease progression. Vol. 4, Future Science OA. Future Medicine Ltd.; 2018.
39. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. *Nature reviews immunology*. 2014 Mar;14(3):181-94.
40. European Association for the Study of the Liver. EASL. EASL 2015 Clinical practice guidelines: Non-invasive test for evaluation of liver disease severity and prognosis. *J Hepatol* 2015;63(1): 237-64.
41. Li C, Li R, Zhang W. Progress in non-invasive detection of liver fibrosis. *Cancer biol med*. 2018;15(2):124-36

42. Soemohardjo S, Gunawan S. Hepatitis B kronik. Setiati S, et al. Buku ajar ilmu penyakit dalam Jilid II Edisi VI. Jakarta: interna publishing. 2015. Hal. 1963-71.
43. Zhang CY, Yuan WG, He P, Hui. Liver Fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. *World J Gastroenterol*. 2016, 22(48):10512-22.
44. Mallat A, Lotersztajn S. Cellular mechanisms of tissue Fibrosis novel insights into liver fibrosis. *American Journal of Physiology-Cell Physiology*. 2013 Oct 15;305(8):C789-99.
45. Zhu CL, Li WT, Li Y, Gao RT. Serum levels of tissue inhibitor of metalloproteinase-1 are correlated with liver fibrosis in patients with chronic hepatitis B. *Journal of digestive diseases*. 2012 Nov;13(11):558-63.
46. Fallatah H. Noninvasive Biomarkers of liver Fibrosis: an overview. *Advances in hepatology*: 2014:1-15.
47. Demir NA, Kolgelier S, Ozcimen S, Gungor G, Sumer S, Demir LS, et al. Evaluation of the relation between hepatic fibrosis and basic laboratory parameters in patients with chronic hepatitis B Fibrosis and basic laboratory parameters. *hepatitis monthly*. 2014 Apr;14(4).
48. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. *Journal of hepatology*. 2012 Jul 1;57(1):167-85.
49. Asselah T, Marcellin P, Bedossa P. Improving performance of liver biopsy in fibrosis assessment. *J Hepatol*. 2014 Aug 1;61(2):193-5.
50. Martinez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. *Hepatology*. 2011 Jan;53(1):325-35.
51. Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, et al. Assessment of liver fibrosis: noninvasive means. *Saudi journal of gastroenterology: official journal of the saudi gastroenterology association*. 2008 Oct;14(4):163.
52. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the knodell histology activity index and beyond. *Hepatology*. 2000 Jan 1;31(1):241-6.

53. Shiha G, Ibrahim A, Helmy, Kumar S. APASL consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. *Hepatol Int*. 2017; 11(1):1-30.
54. Kemp W, Roberts S. FibroScan and transient elastography. *Australian family physician*. 2013 Jul;42(7):468-71.
55. Wilder J, Patel K. Clinical utility of fibroScan as noninvasive diagnostic test for liver disease. *Med Devices: Evidence and research*. 2014; 7:107—14
56. Adebajo CO, Talwalkar JA, Poterucha JJ, Kim WR, Charlton MR. Ultrasoundbased transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. *Liver Transpl*. 2012;18:323-331.
57. Chon YE, Choi EH, Song KJ, Park JY, Han KH, Chon CY et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic Hepatitis B: a meta-Analysis. *PLOS ONE*. 2012;7(9):1-7.
58. Jia J, Hou J, Ding H, Chen G. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic Hepatitis B. 2015; 30(4):756-62.
59. El Hariri, Megid A, Ali T, Hassany M. Diagnostic value of transient elastography (fibroscan) in the evaluation of liver fibrosis in chronic viral hepatitis C: Comparison to liver biopsy. 2017; 48(2):329-52.
60. Friedrich–Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver
61. Amellal N, Raissouni F, Achour J, Guedira M, Kabbaj N, Nya M, et al. Correlation study between liver biopsy and transient elastometry (fibroscan) for the assessment of fibrosis during viral hepatitis C. *Arab journal of gastroenterology*. 2009;2(10):AB17.
62. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, De Lédinghen V, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic Hepatitis B. *Liver international*. 2009 Feb;29(2):242-7.
63. De Ledinghen V, Vergniol J. Transient elastography *Gastroenterologie clinique et biologique*. 2008 Sep 1;32(6):58-67.

64. Dong XQ, Wu Z, Zhao H, Wang GQ, China HepB-Related fibrosis assessment research group. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients. *Journal of viral hepatitis*. 2019 Feb;26(2):297-307.
65. Sheedfar F, Biase SD, Koonen D, Vinciguerra M. Liver diseases and aging: friends or foes? *Aging cell*. 2013 Dec;12(6):950-4.
66. Kim H, Kisseleva T, Brenner DA. Aging and liver disease. *Current opinion in gastroenterology*. 2015 May;31(3):184.
67. Mahrouf-Yorgov M, de l'Hortet AC, Cosson C, Slama A, Abdoun E, Guidotti JE, et al. Increased susceptibility to liver fibrosis with age is correlated with
68. an altered inflammatory response. *Rejuvenation research*. 2011 Aug 1;14(4):353-63.
- Iwaisako K, Brenner DA, Kisseleva T. What's new in liver fibrosis? The
69. origin of myofibroblasts in liver Fibrosis. *Journal of gastroenterology and hepatology*. 2012 Mar;27:65-8.
70. Stahl EC, Haschak MJ, Popovic B, Brown BN. Macrophages in the aging liver and age-related liver disease. *Frontiers in immunology*. 2018 Nov 30;9:2795.
- Wai CT, Cheng CL, Wee A, Dan YY, Chan E, Chua W, et al. Non-invasive
71. models for predicting histology in patients with chronic Hepatitis B. *Liver international*. 2006 Aug;26(6):666-72.
- Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y, et al. A role
72. Wira W, Lopa AT, Samad IA. Analisis KING's score di penyakit hati kronis berdasarkan fibroscan. *Indonesian journal of clinical pathology and medical laboratory*. 2016;22(2):163-7.
73. Maulidia VN, Wardhani P, Setyoboedi B. AST, ALT and albumin level in chronic hepatitis B patients with and without complication of cirrhosis and hepatocellular carcinoma. *Indonesian journal of clinical pathology and medical laboratory*. 2019;26(3):344-9.

74. Mussbacher M, Brunenthaler L, Panhuber A, Starlinger P, Assinger A. Till death do us part-the multifaceted role of platelets in liver diseases. *International journal of molecular sciences*. 2021 Mar 18;22(6):3113.
75. Kurokawa T, Zheng YW, Ohkohchi N. Novel functions of platelets in the liver. *Journal of gastroenterology and hepatology*. 2016 Apr;31(4):745-51.
76. Thong VD, Quynh BT. Correlation of serum transaminase levels with liver fibrosis assessed by transient elastography in vietnamese patients with nonalcoholic fatty liver disease. *International Journal of General Medicine*. 2021 Apr 16:1349-55.
77. Shikdar S, Vashisht R, Bhattacharya PT. International normalized ratio (INR)
79. Wang Y, Dong F, Sun S, Wang X, Zheng X, Huang Y, et al. Increased INR values predict accelerating deterioration and high short-term mortality among patients hospitalized with cirrhosis or advanced fibrosis. *Frontiers in Medicine*. 2021 Nov 18;8:762291.
80. Liu DP, Lu W, Zhang ZQ, Wang YB, Ding RR, Zhou XL, et al. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B. *Journal of viral hepatitis*. 2018 May;25(5):581-9.
81. Lian MJ, Zhang JQ, Chen SD, Zhang DD, Yang YY, Hong GL. Diagnostic accuracy of γ -glutamyl transpeptidase-to-platelet ratio for predicting hepatitis B-related fibrosis: a meta-analysis. *European journal of gastroenterology & hepatology*. 2019 May 1;31(5):599-606.
82. Ekin N, Uemak E, Elib R, Tuncel E, Kaçmaz H, Arpa M et al. GPR, KING's Score and S-Index are superior to other non-invasive fibrosis markers in predicting the liver fibrosis in chronic hepatitis B patients. *Acta gastroenterologica Belgica*. 2022;85(1).
83. Tan Y, Ye Y, Zhou X, Chen L, Wen D. Age as a predictor of significant fibrosis features in HBeAg-negative chronic hepatitis B virus infection with persistently normal alanine aminotransferase. *PLoS One*. 2015 Apr 17;10.
84. Erlina R, Wardhani P, Puspitasari Y, Kholili U. Correlation between APRI, FIB-4 and GPR indices to fibroscan and HBeAg status in patients with chronic

- hepatitis B. Indonesian journal of clinical pathology and medical laboratory. 2021;27:320-5.
85. Cooper KM, Delk M, Devuni D, Sarkar M. Sex differences in chronic liver disease and benign liver lesions. *JHEP Reports*. 2023 Nov 1;5:1–8.
 86. Lapalus M, Laouenan C, Cardoso AC, Estrabaud E, Carvalho-Filho RJ, Zhang et al. Precore/Core promoter variants to predict significant fibrosis in both HB eAg positive and negative chronic hepatitis B. *Liver international*. 2015 Sep;35(9):2082-9.
 87. Mahrouf-Yorgov M, De L'Hortet AC, Cosson C, Slama A, Abdoun E, Guidotti JE, et al. Increased susceptibility to liver fibrosis with age is correlated with an altered inflammatory response. *Rejuvenation res*. 2011 Aug 1;14:353–63.
 88. Stahl EC, Haschak MJ, Popovic B, Brown BN. Macrophages in the aging liver and age-related liver disease. *Front immunol*. 2018 Nov 30;9:1–9.
 89. Maeso-Díaz R, Ortega-Ribera M, Lafoz E, JoséLozano J, Baiges A, Francés R, et al. Aging influences hepatic microvascular biology and liver fibrosis in advanced chronic liver disease. *Aging dis*. 2019;10:684–98.
 90. Cooper KM, Delk M, Devuni D, Sarkar M. Sex differences in chronic liver disease and benign liver lesions. *JHEP Reports*. 2023 Nov 1;5:1-8.
 91. Wang Z, Zhou Y, Yu P, Liu Y, Mei M, Bian Z, et al. Retrospective evaluation of non-invasive assessment based on routine laboratory markers for assessing advanced liver fibrosis in chronic hepatitis B patients. *Int J Gen Med*. 2022;15:5159–71.
 92. Xiong M, Li J, Yang S, Zeng F, Ji Y, Liu J, et al. Influence of gender and reproductive factors on liver fibrosis in patients with chronic hepatitis B infection. *Clin transl gastroenterol*. 2019 Oct 1;10:e00085.
 93. Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration. *World J gastroenterol*. 2017 May 14;23:3228-39.
 94. Sembiring J. Correlation between thrombopoietin serum level and liver fibrosis in chronic hepatitis patients. *the indonesian journal of gastroenterology, hepatology, and digestive endoscopy*. 2010;11:135-41.

95. Galal GM, Maher A, Sayed Ahmed N, Meghezel E-ZM. Validity of different fibrosis scores for assessment of hepatic fibrosis in chronic hepatitis B patients. *ARC Journal of hepatology and gastroenterology*. 2019;4:11-23.
96. Ding R, Zheng J, Huang D, Wang Y, Li X, Zhou X, et al. Inr-to-platelet ratio (Inpr) as a novel noninvasive index for predicting liver fibrosis in chronic hepatitis b. *Int J Med Sci*. 2021;18:1159-66.
97. Korkmaz P, Demirturk N, Batirel A, Cem Yardimci A, Cagır U, Nemli SA, et al. Noninvasive models to predict liver fibrosis in patients with chronic hepatitis B: A study from Turkey. *Hepat Mon*. 2017 Dec 1;17.
98. Islam R, Kundu S, Jha SB, Rivera AP, Flores Monar GV, Islam H, et al.
99. Cirrhosis and coagulopathy: mechanisms of hemostasis changes in liver failure and their management. *Cureus*. 2022 Apr 3;
Harrison MF. The misunderstood coagulopathy of liver disease: A review for
100. the acute setting. Vol. 19, *Western journal of emergency medicine*.
Scholarship; 2018. p. 863–71.
Zeng X, Xu C, He D, Li M, Zhang H, Wu Q, et al. Performance of several
101. simple, noninvasive models for assessing significant liver fibrosis in patients
with chronic hepatitis B. *Croat Med J*. 2015;56:272–9.
Xing M, Gao M, Li J, Han P, Mei L, Zhao L. Characteristics of peripheral
102. blood Gamma-glutamyl transferase in different liver diseases. *Medicine*. 2022
Jan 7;101(1):e28443.
fibrosis in patients with nonalcoholic fatty liver disease: A community-based
cross-sectional study. *Kaohsiung journal of medical sciences*. 2021
Sep;37(9):819-27.
103. Hu YC, Liu H, Liu XY, Ma LN, Guan YH, Luo X, et al. Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B. *World J gastroenterol*. 2017 Nov 7;23:7425–32.

104. Kim SU, Lee JH, Kim DY, Ahn SH, Jung KS, Choi EH, et al. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. *PLoS One*. 2012 May 4;7.
105. Alsebaey A, Badr R, Abdelsameea E, Amer MO, Eljaky MA, El-Azab G, Salama M. King's fibrosis, fibrosis index, GPR, and ALBI score are useful models for liver fibrosis in chronic hepatitis B patients pre-and post-treatment. *Hepatitis monthly*. 2019;19(11).
106. Cf J, Bs U, Dl S, Ia G, Dr T, Me C, et al. Quantification of liver fibrosis in chronic hepatitis B virus infection. *J Med Life*. 2015;8:285–90.
107. Dong B, Lyu G, Chen Y, Lin G, Wang H, Qin R, et al. Comparison of two-dimensional shear wave elastography, magnetic resonance elastography, and three serum markers for diagnosing fibrosis in patients with chronic hepatitis B: a meta-analysis. *Expert rev gastroenterol hepatol*. 2021;15:1077–89.
108. Hamidi AA, Oncul A, Ozguven BY, Sevgi DY, Gunduz A, Uzun N, et al. Diagnostic accuracy of different noninvasive scores for detecting advanced fibrosis in chronic hepatitis B. *Eur J gastroenterol hepatol*. 2019 Nov 1;31:1439–43.
109. Çelik D, Tatar B, Köse Ş, Ödemiş İ. Evaluation of the diagnostic validity of noninvasive tests for predicting liver fibrosis stage in chronic hepatitis B patients. *Acta gastro-ent Belg*. 2020 Jul 1;83:419-25.
110. Okdemir S, Cakmak E. A novel non-invasive score for the prediction of advanced fibrosis in patients with chronic hepatitis B. *Ann Hepatol*. 2022 Jan 1;27
111. Zhuang Y, Ding H, Zhang Y, Sun H, Xu C, Wang W. Two-dimensional shear-wave elastography performance in the noninvasive evaluation of liver Fibrosis in patients with chronic Hepatitis B: comparison with serum fibrosis indexes. *radiology*. 2017 Jun 1;283:873-82.
112. Khare S, Arora A, Sharma P, Dhawan S, Bansal N, Singla V, Kumar A. Performance of non-invasive blood parameters for ruling out significant liver fibrosis in patients with chronic hepatitis B. *Journal of clinical and translational hepatology*. 2020 Jun 6;8(2):143.

113. Ding R, Zhou X, Huang D, Wang Y, Li X, Yan L, et al. Predictive performances of blood parameter ratios for liver inflammation and advanced liver fibrosis in chronic hepatitis B infection. *Biomed res Int.* 2021;2021.
114. Wang L, Li J, Yang K, Zhang H, Wang Q, Lv X, et al. Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels. *Medicine (Baltimore).* 2020;99.
115. Li Q, Li W, Huang Y, Chen L. The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBeAg-positive chronic VHB infection patients with high VHB DNA and normal or mildly elevated alanine transaminase levels in China. *J viral hepat.* 2016 Nov 1;23:912–9.
116. Li Q, Song J, Huang Y, Li X, Zhuo Q, Li W, et al. The gamma-glutamyl-transpeptidase to platelet ratio does not show advantages than APRI and fib-4 in diagnosing significant fibrosis and cirrhosis in patients with chronic hepatitis B A retrospective cohort study in China. *Medicine (Baltimore).* 2016;95.
117. Lee J, Kim MY, Kang SH, Kim J, Uh Y, Yoon KJ, et al. The gamma-glutamyl transferase to platelet ratio and the FIB-4 score are noninvasive markers to determine the severity of liver fibrosis in chronic Hepatitis B infection. *Br J biomed Sci.* 2018 Jul 3;75:128–32.
118. Kaya A, Barutcu S, Gulsen MT. Evaluation of fibrosis with noninvasive biochemical tests in chronic viral hepatitis B. *Hepato Forum.* 2023;4:25–9.
119. Lian MJ, Zhang JQ, Chen SD, Zhang DD, Yang YY, Hong GL. Diagnostic accuracy of γ -glutamyl transpeptidase-to-platelet ratio for predicting Hepatitis B-related Fibrosis: A meta-analysis. *Eur J Gastroenterol Hepatol.* 2019 May 1;31:599–606.
120. Wu X, Cai B, Su Z, Li Y, Xu J, Deng R, et al. Aspartate transaminase to platelet ratio index and gamma-glutamyl transpeptidase-to-platelet ratio outweigh fibrosis index based on four factors and red cell distribution width-platelet ratio in diagnosing liver Fibrosis and inflammation in chronic hepatitis B. *J Clin Lab Anal.* 2018 May 1;32.

121. Purkayastha S, Jha AK, Kumar R, Dayal VM, Jha SK. Serum gamma-glutamyl transpeptidase-to-platelet ratio as a noninvasive marker of liver fibrosis in chronic hepatitis B. *Cureus*. 2023 Jan 13;
122. Li Q, Chen L, Zhou Y. Diagnostic accuracy of liver stiffness measurement in chronic hepatitis B patients with normal or mildly elevated alanine transaminase levels. *Sci Rep*. 2018 Dec 1;8.
78. Wan R, Liu H, Wang X, Wan G, Wang X, Zhou G, et al. Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B. *Int J Clin Exp Med*. 2015;8:961–71

